PROFESSIONAL DRUG COMPANY, INC. v. WYETH, INC.

  1. October 18, 2024

    Teva Signs Deal With Indirect Buyers In Effexor Antitrust Suit

    A class of consumers and third-party payers have reached a deal with Teva Pharmaceuticals to resolve antitrust litigation over a purported scheme to delay generic competition for the antidepressant drug Effexor XR, according to a court filing.

  2. June 11, 2024

    10 Firms Seek $13M Fee For Effexor Antitrust Deal

    Ten law firms asked a New Jersey federal judge on Monday to award $13 million in counsel fees and an additional $2.1 million in costs for representing direct buyers in a $39 million settlement with Pfizer Inc. unit Wyeth over an alleged scheme to delay generic competition for the antidepressant drug Effexor XR.

  3. April 29, 2024

    Pfizer Inks $25M Deal Ending Leftover Effexor Antitrust Claims

    A proposed class of indirect buyers have asked a New Jersey federal judge to greenlight a $25.5 million settlement to end allegations that Pfizer unit Wyeth engaged in a scheme with Teva Pharmaceuticals to delay generic competition for the antidepressant Effexor XR.

  4. April 10, 2024

    Pfizer Unit Cuts $39M Deal Ending Effexor Antitrust Claims

    A proposed class of direct buyers asked a New Jersey federal judge on Tuesday to approve a $39 million settlement to end allegations that Pfizer Inc. unit Wyeth engaged in a scheme with Teva Pharmaceuticals to delay generic competition for the antidepressant drug Effexor XR.

  5. January 16, 2015

    Effexor Buyers To Take Antitrust Suit To 3rd Circ.

    Walgreen Co., Rite Aid Corp. and other drug buyers notified a New Jersey federal judge on Thursday that they would be appealing to the Third Circuit his decision to dismiss their claim against Wyeth Inc. and Teva Pharmaceuticals USA Inc. over a no-authorized-generic deal for antidepressant Effexor XR.

  6. October 22, 2014

    Effexor Buyers Want Another Chance In Antitrust Suit

    Drug buyers on Tuesday urged a New Jersey federal judge to allow them to amend their complaint against Wyeth Inc. and Teva Pharmaceuticals USA Inc. over a no-authorized-generic deal for antidepressant Effexor XR, saying the court's new pleading standard is novel and was only introduced after they filed their suit.

  7. June 19, 2014

    Purchasers Blast Wyeth's Immunity Bid In Pay-For-Delay Suit

    A class of direct purchasers accusing Wyeth LLC and Teva Pharmaceuticals USA Inc. of making an anti-competitive deal to delay a generic version of the antidepressant Effexor XR criticized Wyeth on Thursday for trying to use an old consent decree to bolster its immunity argument, claiming the decree was brought up too late.

  8. May 01, 2014

    Wyeth Claims Immunity Against Effexor Pay-For-Delay Suit

    Wyeth LLC told a New Jersey federal judge on Wednesday that U.S. Supreme Court precedent gave it immunity against antitrust claims from a class of drug wholesalers accusing it of making a deal with Teva Pharmaceuticals USA Inc. to delay a generic version of antidepressant Effexor XR.

  9. August 16, 2013

    FTC Wants To Extend Actavis To Authorized Generics Deals

    The Federal Trade Commission on Wednesday urged a New Jersey federal judge overseeing private antitrust litigation targeting an authorized generics deal between Wyeth LLC and Teva Pharmaceuticals USA Inc. to apply the U.S. Supreme Court's recent pay-for-delay ruling to the case.

  10. October 04, 2012

    FTC Can't Weigh In On Effexor Authorized Generics Case

    A New Jersey federal judge refused Wednesday to let the Federal Trade Commission weigh in on private antitrust litigation targeting an authorized generic deal between Wyeth LLC and Teva Pharmaceuticals USA Inc., ruling the agency's partiality made it an ill-suited amicus.